Chad Cowan, Clade Therapeutics CEO

CRISPR Ther­a­peu­tics co-founder un­cloaks an off-the-shelf cell ther­a­py start­up with $87M and a lot of fan­fare

When Chad Cow­an was re­cruit­ed to Har­vard Uni­ver­si­ty 20 years ago to work on hu­man em­bry­on­ic stem cells, he was in­spired by the idea that these spe­cial­ized cells could be used to make in­sulin-pro­duc­ing be­ta cells and po­ten­tial­ly cure Type 1 di­a­betes.

How­ev­er, he soon re­al­ized if those cells were go­ing to do it, they would need to over­come the im­mune re­sponse that the body nat­u­ral­ly mounts against for­eign bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.